JP2011518115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518115A5 JP2011518115A5 JP2010543588A JP2010543588A JP2011518115A5 JP 2011518115 A5 JP2011518115 A5 JP 2011518115A5 JP 2010543588 A JP2010543588 A JP 2010543588A JP 2010543588 A JP2010543588 A JP 2010543588A JP 2011518115 A5 JP2011518115 A5 JP 2011518115A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- tapasin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 210000004027 cell Anatomy 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 102100028082 Tapasin Human genes 0.000 claims 12
- 230000028993 immune response Effects 0.000 claims 12
- 108010059434 tapasin Proteins 0.000 claims 12
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 claims 6
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims 6
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700647 Variola virus Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000000270 basal cell Anatomy 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000013600 plasmid vector Substances 0.000 claims 2
- 201000008261 skin carcinoma Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2400408P | 2008-01-28 | 2008-01-28 | |
| US61/024,004 | 2008-01-28 | ||
| PCT/IB2009/005030 WO2009095796A2 (en) | 2008-01-28 | 2009-01-27 | Tapasin augmentation for enhanced immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014130452A Division JP2014196338A (ja) | 2008-01-28 | 2014-06-25 | 免疫応答を増強するためのタパシン増加 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518115A JP2011518115A (ja) | 2011-06-23 |
| JP2011518115A5 true JP2011518115A5 (OSRAM) | 2011-08-11 |
Family
ID=40913348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543588A Pending JP2011518115A (ja) | 2008-01-28 | 2009-01-27 | 免疫応答を増強するためのタパシン増加 |
| JP2014130452A Pending JP2014196338A (ja) | 2008-01-28 | 2014-06-25 | 免疫応答を増強するためのタパシン増加 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014130452A Pending JP2014196338A (ja) | 2008-01-28 | 2014-06-25 | 免疫応答を増強するためのタパシン増加 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110117137A1 (OSRAM) |
| EP (1) | EP2247309A4 (OSRAM) |
| JP (2) | JP2011518115A (OSRAM) |
| KR (1) | KR20110011595A (OSRAM) |
| CN (1) | CN102159241A (OSRAM) |
| AU (1) | AU2009208735A1 (OSRAM) |
| CA (1) | CA2712964A1 (OSRAM) |
| WO (1) | WO2009095796A2 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12397036B2 (en) | 2018-01-26 | 2025-08-26 | Cambridge Enterprise Limited | Peptide exchange protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0783573B1 (en) * | 1994-09-23 | 2005-12-21 | The University of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| US6171820B1 (en) * | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6479258B1 (en) * | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6713279B1 (en) * | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6692923B2 (en) * | 1999-04-14 | 2004-02-17 | Incyte Corporation | Tapasin-like protein |
| DK1363938T3 (en) * | 2000-08-03 | 2014-03-24 | Univ Johns Hopkins | Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen |
| JP2004517917A (ja) * | 2000-11-08 | 2004-06-17 | アルバート・アインシュタイン・カレッジ・オブ・メディシン・オブ・イエシヴァ・ユニバーシティー | 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法とその使用 |
| GB0328248D0 (en) * | 2003-12-05 | 2004-01-07 | Oxford Biomedica Ltd | Method |
-
2009
- 2009-01-27 KR KR1020107016543A patent/KR20110011595A/ko not_active Ceased
- 2009-01-27 EP EP09705684.0A patent/EP2247309A4/en not_active Withdrawn
- 2009-01-27 US US12/864,751 patent/US20110117137A1/en not_active Abandoned
- 2009-01-27 WO PCT/IB2009/005030 patent/WO2009095796A2/en not_active Ceased
- 2009-01-27 JP JP2010543588A patent/JP2011518115A/ja active Pending
- 2009-01-27 CA CA2712964A patent/CA2712964A1/en not_active Abandoned
- 2009-01-27 CN CN2009801031574A patent/CN102159241A/zh active Pending
- 2009-01-27 AU AU2009208735A patent/AU2009208735A1/en not_active Abandoned
-
2014
- 2014-06-25 JP JP2014130452A patent/JP2014196338A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | mRNA vaccines in disease prevention and treatment | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| ES2848064T3 (es) | Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas | |
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| ES2522042T3 (es) | Composición de vacuna que comprende un ARN modificado con caperuza 5' | |
| Alemany | Viruses in cancer treatment | |
| JP2017514483A5 (OSRAM) | ||
| US12220456B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2016516723A5 (OSRAM) | ||
| WO2014022138A3 (en) | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator | |
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| Öhlschläger et al. | Enhancement of immunogenicity of a therapeutic cervical cancer DNA‐based vaccine by co‐application of sequence‐optimized genetic adjuvants | |
| Liu et al. | Therapeutic use of tumor cell-derived extracellular vesicles | |
| Xie et al. | Overcoming suppressive tumor microenvironment by vaccines in solid tumor | |
| CN103619350A (zh) | 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法 | |
| CN121038810A (zh) | 针对冠状病毒感染、流行性感冒感染和/或rsv感染的组合疫苗 | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| Zinovieva et al. | Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies | |
| JP2011518115A5 (OSRAM) | ||
| US11331343B2 (en) | Compositions and methods for activating antigen presenting cells with chimeric poliovirus | |
| CN106794208B (zh) | 用于处理癌细胞的组合物及其方法 | |
| Ratre et al. | Molecular farming and anticancer vaccine: current opportunities and openings | |
| Bahreyni | Development of a safe treatment for breast cancer using an oncolytic Coxsackievirus B3 | |
| Wu et al. | A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment |